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The extraordinary versatility of the antibody-forming mechanism in producing an 
almost limitless number of specific receptor sites complementary for almost any molec- 
ular conformation of matter within a size range (1-3) represented by a hexa- or hepta- 
saccharide as an upper and a mono- or disaccharide as a lower limit, is almost certainly 
related to the unique structural features of immunoglobulins and differentiates them 
from all other known proteins. These antibody-combining sites are formed as a  con- 
sequence of the interaction of two polypeptide chains, a light and a heavy chain (2, 4, 
5). The antibodies usually formed to various antigens often represent heterogeneous 
populations of immunoglobulin molecules of different classes, subclasses, and genetic 
variants and also show specificities tgward different antigenic determinants (1, 2, 6, 7). 
In some instances, however, relatively homogeneous populations of antibodies with 
respect to many of these properties have been obtained. Among these have been human 
antibodies to dextran and levan (8, 9) and rabbit antibodies to the group-specific  carbo- 
hydrate of streptococcus (10-12), antibodies to the Type III-specific capsular poly- 
saccharide of pneumococcus (13,  14),  rabbit antihapten (15), and specimens of anti- 
bodies and of Fab' fragments which crystallized (Nisonoff et al., in references 16, 17), 
but sequence data on these are not yet available. 
The large body of sequence data related to immunoglobulin structure comes from 
the analysis of urinary Bence Jones proteins and from the monoclonal immunoglobu- 
lins found in large amounts in the sera of patients with multiple myeloma and Walden- 
strtim macroglobuUnemia (16, 18). While a substantial body of evidence was available 
relating  these  proteins  to  immunoglobulins,  the  recent  demonstration  that  many 
myeloma globulins have specific ligand-binding properties like those of many  anti- 
bodies provides increasing confidence that myeloma globulins represent homogeneous 
populations of  antibody molecules (16,  18-27).  The  ability to produce in  BALB/c 
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mice myelomas and macroglobulinemias (28) which produce myeloma globulins and 
Bence Jones proteins like those in the human, provides a source of data from which 
important evolutionary trends can be inferred. 
Thus the extensive sequence data on Bence Jones proteins, which are considered to 
be light chains of myeloma globulins and Waldenstriim macroglobulins (29),  and on 
various light and heavy chains, provide information clearly pertinent to the problem 
of the elucidation of the structure of antibody-combining sites. 
The unique finding that distinguishes the immunoglobulins from all other proteins is 
that the N-terminal half of the light chains and the N-terminal quarter of the heavy 
chains vary in  sequence in samples  obtained  from individual  monoclonal immuno- 
globulins and that indeed no two such variable regions of any chain and no two mye- 
loma immunoglobulins or Bence Jones proteins have thus far been found to be identical 
in sequence (30). The constant region,  however, is essentially no different from other 
proteins in that the variation in the amino acids found at any position is ascribable 
to species  and class variations or to genetic variants  such  as Inv factors.  By com- 
parison of sequence data on the variable and constant regions of Bence Jones proteins 
with  amino acid composition of purified human antibodies,  it could be shown that 
most of the compositional variation could only originate in the variable region (see 
Kabat in reference 18). 
From  sequence data,  a  variety of hypotheses have been advanced  (7,  31-35)  to 
explain  the structural basis  of antibody complementarity.  All of these are selective 
theories, i.e. they consider that the information for complementarity is essentially built 
into the primary sequence of each chain and that a given antigen only triggers the 
biosynthesis of those antibody molecules  having complementary receptor sites.  There 
are  two  types  of  selective  theories:  germ  line  theories  (36)  and  somatic  mutation 
theories  (37-39).  At present  no hypothesis is  generally accepted.  Excellent reviews 
(see above) are available. 
The present communication is an extension of earlier efforts from this labora- 
tory (18, p.  87, and 40-43)  to locate more precisely those portions of the vari- 
able region which are directly responsible for antibody complementarity,  that 
is  which  make  direct  contact with  the  antigenic  determinant,  and  to explain 
the unique capacity of these proteins to have so many complementary regions. 
As in the  earlier  studies,  all  human K,  human X,  and mouse  K Bence Jones 
protein  and  light  chain  sequences  are  aligned  for  maximum  homology  (44) 
and  all variable  regions are  considered  as a  unit and compared with  the  con- 
stant regions. These earlier studies had called attention  to the following: 
(a)  The variable  regions had few if any species-specific positions  while  the 
constant  regions  of  the  human  and  mouse  proteins  had  36  species-specific 
amino acid substitutions  per  107  residues  (40,  45).  A  species-specific position 
is defined as one at which the amino acid residues in the mouse proteins differ 
from those in the human proteins. 
(b)  When  the  invariant  residues  of  these  two  regions  were  compared,  the 
latest  tabulation  (45)  showed  the  variable  regions  to have  10  invariant  and 
almost  invariant  glycines  and  no  invariant  alanines,  leucines,  valines,  histi- TAI  TE  WU  AND  ELVIN  A.  KABAT  213 
dines,  lysines,  or  serines while  the  constant  regions had  3  each  of invariant 
alanine, leucine, and valine, and 2 invariant histidines, 2 invariant lysines, and 
5 invariant serines. It was suggested that the invariant glycines were important 
in  contributing to the flexibility needed by the variable region in  accommo- 
dating  the  numerous substitutions  (41,  43)  at  the variable  positions. It was 
also suggested that the invariant glycines near the end of the variable region 
at  positions  99  and  101,  plus  the  almost  invariant  glycine at  position  100, 
provided a pivot upon which the complementarity-determining regions might 
move to make better contact with  the antigenic determinant (43;  18,  p.  87) 
just as the walls of the lysozyme site have been shown to adjust somewhat to 
accommodate its hexasaccharide substrate  (46).  The hydrophobic residues in 
the constant region were hypothesized to be involved in noncovalent bonding 
to the heavy chain. 
(c)  From an  examination of sequences of the  ~I,  KII,  and  ~III  subgroups 
(Hood et al.  in reference 16)  (47,  48)  of the human  Bence Jones proteins in 
which many of the proteins in a  subgroup had an identical sequence for the 
first 2(~24 residues, it was postulated that there are two kinds of residues in 
the variable regions, those making direct contact with the antigenic determi- 
nant  (complementarity determining)  and  those  which  are  involved  only in 
three-dimensional  folding  (42).  The  latter  would  be  expected  to  have  less 
stringent  requirements,  and  more  mutation  noise  would  be  permitted  than 
with  the  complementarity-determining residues.  This  distinction  led  to  the 
inspection of the sequences for short stretches showing very high variability 
and  two of these were identified: the most variable beginning  at residue  89 
and ending at 97, the other running from residue 24 through 34. Each of these 
two  unusually highly variable  regions  began  after  an  invariant  half-cystine 
and was followed by an invariant phenylalanine (residue 98) and an invariant 
tryptophane (residue 35) respectively. It is of interest that the two regions are 
brought close together by the S--S bond I2~-II88 (45). Milstein  (47), Milstein 
and Pink (7), and Fran~k (49) have also called attention to the highly variable 
positions  in  these  regions  and  Fran~k  (49)  has  noted  an  additional  highly 
variable region around residues 52-55. It was hypothesized (45) that these first 
two  regions  might  represent  the  complementarity-determining  regions  and 
that  complementarity might be acquired by the insertion of small linear se- 
quences into the light and heavy chains by some episomal or other insertion 
mechanism. It is striking that the differences in chain length seen in the Bence 
Jones proteins are confined to these two regions of the chain.  The remaining 
portions  of  each  chain  would  be  essentially  under  the  control of  structural 
genes.  The inserted sequences would be drawn from a large but finite set and 
either  inserted  under  the  influence of  antigen,  if  antibody-forming cells are 
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forming cells during differentiation if the capacity of individual cells to synthe- 
size antibody is restricted. 
This working hypothesis offers several  advantages: 
(a)  It is  capable  of providing the  evolutionary stability  and  accounts for 
the  universality  of  the  antibody-forming mechanism  throughout  the  verte- 
brates.  Germ line  theories (34-36) postulate one gene for each of the thousand 
or more variable regions  (30).  This would be expected to result in divergence 
during evolution since the loss by mutation of any one variable region would 
only minimally affect the  capacity to form antibody and survival; thus indi- 
viduals and populations lacking certain variable regions would arise. 
(b) It offers  a substantial simplification to the problem of producing a very 
large number of complementary sites.  While  it is  known that  in  all  proteins 
with  specific  receptors  the  site  is  formed by residues  from widely separated 
portions of the chain,  these sites are all formed by single  chains.  Thus, form- 
ing a  three-dimensional site  must involve residues  from various regions.  The 
antibody site being formed by a heavy and a light chain need not necessarily 
be so restricted. 
Since much additional data on the light chains and a number of heavy chain 
sequences  have  been  accumulated,  the  present  communication  represents  a 
further  attempt  at  analyzing  the  unique  features  of  the  variable  regions  of 
immunoglobulin  chains.  Among  aspects  considered  are  the  role  of  glycine, 
invariant residues,  and hydrophobicity patterns,  and  the highly variable por- 
tions,  with  a  view  to  localizing  the  regions  responsible  for  complementarity 
and evaluating various theories in terms of evolutionary origin and perpetua- 
tion of the antibody-forming mechanism. 
Sequence  Data  Employed--Complete  and  partial  sequence  data  have  been 
published on 77 Bence Jones proteins and immunoglobulin light chains as well 
as on a number of heavy chains.  Data were available on 24 human KI, 4 human 
KII, 17 human dII, l0 human M, 2 human MI, 6 human MII, 5 human MV, 
2 human XV, 2 mouse KI, and 5 mouse KII proteins. 1 
The original light chain sequence data may be found in the following references. 
HBJ 98:  Baglioni,  C. 1967. Biochem. Biophys. Res. Commun. 26:82. 
Eu:  Cunningham, B. A., P. D.  Gottlieb, W. H. Konigsberg, and  G. M. Edelman. 1968. 
Biochemistry. 7:1983. 
Mil  (human dI):  Dreyer, W.  J.,  W.  R.  Gray, and L. Hood. 1967. Cold Spring  Harbor 
Syrup.  Quant. Biol. 32:353. 
Hac, Dob, Pal:  Grant, A., and L. Hood. Unpublished work. 
Roy, Cum:  Hilschman,  N., and L. C. Craig. 1965. Proc. Nat Acad. Scl.  U. S. A. 53"1403; 
Hilschmann, N.  1967. Hoppe-Seyler's Z.  Physiol. Chem. 348:1077; Hilschmann, N., 
H. U. Barnikol, M. Hess, B. Langer, H. Ponstingl, M. Stelnmetz-Kayne, L. Suter, and 
S. Watanabe. 1968. Fed. Eur.  Biochem. Soc. Syrup., 5th. In press. 
1  The World Health Organization has recently changed the notation of subgroups so that 
human ~II in this paper will become  human ~[II and human rIII will become  human KII. TA1  TE  WU  AND  ELVIN  A.  KABAT  215 
HS 78, HS 92, HS 94, HS 68, HS 70, HS 77, HS 86, HS 24:  Hood, L., and D. Ein. 1968. 
Nature  (London).  220:754. 
HBJ 7, HBJ 11, HBJ 2, HBJ 8:  Hood, L., W. R. Gray, and W. J. Dreyer. 1965. J. Mol. 
Biol.  22:179. 
MBJ 41, MBJ 70, MBJ 6:  Hood,  L., W. R.  Gray, and W. J.  Dreyer. 1966. Proc.  Nat'l 
Acad.  Sci.  U. S. A. 55:826. 
HBJ 10, HBJ 1, HBJ 4, HBJ 6, HBJ 5, HS 4, HBJ 12, HS 6, HBJ 15:  Hood, L., W. R. 
Gray, B. G. Sanders,  and W. J. Dreyer. 1967. Cold Spring Harbor  Symp. Qnant.  Biol. 
32:133. 
Ste:  Edman, P., and A. G. Cooper.  1968 Fed.  Eur.  Biochem  Soc.  Letters. 2:33; Hood, L., 
and  D.  W.  Talmage.  1969. In  Developmental Aspects of  Antibody Formation and 
Structure.  Prague.  In press. 
Lay, Mar, Ioc, Wag, How, Koh:  Kaplan, A. P. and H. Metzger.  1969. Biochemistry.  10: 
3944. 
New, III, Mil (human  XIV):  Langer, B., M. Steinmetz-Kayne, and N. Hilschmann. 1968. 
Hoppe-Seyler's  Z. Physiol.  Chem.  349:945. 
BJ, Ker:  Milstein, C.  1966. Biochem.  J.  101:352. 
Rad, Fr4:  Milstein,  C. 1967. Nature (London)  216:330. 
X:  Milstein, C. 1968. Biochem. J. 110:631. 
Bel,  Man,  B6:  Milstein, C.  1968. Fed.  Eur.  Biochem.  Soc.  Symp.  on  "~-globulin, Prague. 
Day, MBJ46,  Roy:  Atlas of Protein Sequence and Structure, M. O. Dayhoff, Editor. 1969. 
Mz:  Milstein,  C., B. Frangione, and J. R. L. Pink. 1967. Cold Spring Harbor Symp. Quant. 
Biol.  32:31. 
Ale, Car, Dee:  Milstein, C., C. P. Milstein, and A. Feinstein. 1969. Nature (London) 221:151. 
Cra, Pap, Lux, Mon,  Con, Tra, Nig, Win, Gra, Cas, Smi:  Niall, H., and P. Edman.  1967. 
Nature  (London)  216:262. 
MOPC  149, AdjPC 9, MOPC  157:  Perham, R., E. Appella, and M. Potter. 1966. Science 
(Washington)  154:391. 
Kern:  Ponstingl,  H., M. Hess, and N. Hilschmann.  1968. Hoppe-Seyler's  Z. Physiol. Chem. 
349:867. 
Tew:  Putnam, F. W. 1969. Science  (Washington).  163:633. 
Ag, Ha, Bo, Sh:  Putnam, F. W., K. Titani, M. Wikler, and T. Shinoda.  1967. Cold Spring 
Harbor Symp. Quant.  Biol.  32:9; Titani, K., T. Shinoda,  and F. W. Putnam.  1969. J. 
Biol.  Chem.  244:3550. 
TI:  Suter, L., H. U. Barnikol,  S. Watanabe, and N. Hilschmann.  1969. Hoppe-Seyler's  Z. 
Physiol.  Chem.  1150:275. 
The accumulation of such large numbers of sequences makes it possible to use 
statistical criteria  in  defining  the  types  of  residues.  Thus  in  earlier studies, 
an invariant  residue was rigidly defined,  e.g.,  a  position at  which all samples 
showed  the  same  amino  acid  residue  sometimes  allowing a  single  exception. 
The definition of an  invariant residue used in this paper is taken as a position 
at which  88-90 %  or more of the samples contain  the same amino acid.  This 
may  allow  potential  functions  to  be  recognized  despite  possible  errors  or 
uncertainties in sequence, or occasional substitutions compatible with function. 
A summary of the sequence data is provided in Table I  which lists the amino 
acids found at any position in any subgroup of human K-, human X-, and mouse 
K-chains, the number of times each occurs, and the total number of sequences 216  BENCE  JONES  PROTEINS  AND  MYELOMA  LIGHT  CHAINS 
TABLE  I 
Amino Acids Found at each Position  in the Variable Region of the Various Subgroups of Human 
~-,  Human  X- and  Mouse  •-Bence  Jones  Proteins 
No.  of 
Protein  Amino  Human Kappa  Human Immbda  Mouse Kappa  Position  Total 
Sequences  Acids  III  IIl  III  Ill IV  V  I  II 
Studied 
0  74  Glu  i  0  i  0  O  0  O  O  O  0  0 
---  73  23  3 17  9  2  6  4  2  2  5 
i  74  Lys  i  O  0  i  0  0  0  O  0  0  0 
PCA  17  0  0  0  8  2  6  0  0  0  i 
Asp  29  18  4  i  0  0  O  0  0  2  4 
Asx  5  5  O  0  0  O  O  O  O  0  0 
Glu  15  0  0  14  i  0  0  O  O  0  0 
Glx  i  O  0  i  0  O  O  O  O  0  0 
---  6  O  0  0  0  0  0  4  2  0  0 
2  73  lle  48  22  3 16  O  0  0  0  0  2  5 
Tyr  4  00  0  O  O  0  4  0  0  0 
Val  i  I  0  0  0  0  0  0  O  0  0 
Met  i  O  0  i  O  O  0  0  O  O  0 
Ser  19  O  0  O  9  2  6  0  2  O  0 
3  72  lle  i  O  0  I  0  0  0  O  0  O  O 
Pro  i  0  0  0  0  0  i  0  0  0  0 
Leu  i  i  0  0  0  0  0  0  0  0  0 
Val  33  0  3 16  8  0  0  i  0  0  5 
Ala  9  0  0  0  1  2  5  i  0  O  0 
Asp  i  0  0  0  0  0  0  i  0  0  0 
Glu  2  0  O  0  O  0  0  i  i  O  O 
Gln  21  19  0  0  0  0  O  0  0  2  0 
Glx  3  3  O  O  O  0  O  O  O  O  0 
4  71  Leu  43  3  i lh  9  2  6  4  i  0  3 
Val  2  0  O  i  0  O  0  O  O  0  i 
Met  26  20  2  2  0  O  O  O  0  2  0 
5  7o  Ala  2  0  00  O  0  2  O  O  0  0 
The  67  23  3 17  9  2  3  4  1  2  3 
Ser  i  0  0  O  O  0  i  0  O  0  0 
6  69  Gln  63  20  3 16  8  1  6  4  1  i  3 
Glx  6  30  i  i  i  O  0  0  O  O 
7  63  Pro  20  O  0  0  9  2  6  3  0  0  0 
Thr  i  0  i  0  0  0  0  0  0  0  0 
Ser  41  22  2  14  0  O  0  0  O  i  2 
Asp  i  O  O  0  O  0  0  0  i  0  0 TAI TE WU  AND  ELVIN  A. KABAT  217 
TABLE  I--Contlnued 
No.  of 
Protein  Amino  Position  Total  Sequences  Acids 
Studied 
8  64  Pro  98  22  315 
Ala  6  0  0  0 
9  63  Leu  3  0  30 
Ala  7  0  0  4 
Thr  i  i  0  0 
Ser  41  21  0  0 
Gly  i0  0  0 i0 
Asx  1  0  0  1 
lO  63  Phe  1  1  0  0 
Th~  17  3  014 
Ser  25  18  4  0 
---  20  0  0  0 
ii  63  Leu  43  22  414 
Val  15  0  0  0 
Ala  5  0  0  0 
12  61  Pro  4  0  40 
Ala  i  0  0  0 
Set  56  21013 
13  61  Leu  12  0  012 
Val  ii  2  4  0 
Met  i  0  0  1 
Ala  23  19  0  0 
Oly  14  0  0  0 
14  61  Ala  6  0  0  0 
Thr  9  o  4  o 
Ser  46  21  013 
19  61  Pro  36  0  413 
Leu  4  i  0  0 
Val  20  20  0  0 
Asx  i  0  0  0 
16  61  krg  i  i  0  0 
Gly  60  20  4  13 
17  61  Asp  23  210  1 
Glu  17  0  4 ii 
Gln  19  0  0  0 
Glx  2  0  0  i 
Human Kappa  Human Lambda  Mouse Kappa 
I II IIl  I II III IV  V  I  II 
920  31  12 
OO6  00  0  0 
00000  O0 
00001  02 
000  00  00 
926  20  i  o 
00000  O  O 
00000  O0 
00000  O0 
00000  O0 
00000  12 
9  2  6  2  l  0  0 
000  O0  12 
6  06  2  1  0  0 
32000  00 
000  00  00 
00000  01 
92621  ii 
00000  0  0 
00021  02 
00000  00 
30000  i0 
626  O0  O0 
50001  O0 
40000  0  i 
02620  ii 
826  2o  o  l 
00001  ii 
00000  O0 
i00  O0  0  0 
00000  O0 
9  2  6  2  i  i  2 
00000  01 
00100  i0 
825  21  0  1 
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TABLE I--Continued 
No.  of 
Protein  Amino  Human Kappa  Human L~mbda  Mouse Kappa 
position  Sequences  Acids  Total  III  Iii  III  III IV  V  I  II 
S  t  udie  s 
18  61  Pro  4  0  4  0  0  0  0  0  O 
Lys  i  0  0  0  i  O  0  0  0 
Ala  i  0  0  0  i  0  0  0  0 
Arg  4O  21  O  13  400  O  O 
Tbm  ~  0  0  0  i  O  i  2  1 
8er  9  0  O  O  i  2  5  0  O 
Gly  i  00  0  i  O  0  O  0 
19  53  Ile  7  l  0  0  0  0  6  0  0 
Val  28  17  O  0  6  2  0  0  i 
Ala  18  O  4 i0  i  O  O  2  O 
20  53  Ile  i  O  O  O  I  O  O  0  O 
Val  i  0  0  0  O  0  0  i  0 
Ala  3  i  0  2  O  0  0  0  O 
Arg  i  O  0  0  0  0  O  0  i 
Thr  40  17  O  8  6  2  6  00 
Ser  7  0  4  0  O  0  O  I  O 
21  43  lle  30  14  4  0  ~  2  0  3  1 
Leu  12  i  O  9  O  O  O  O  0 
VafL  i  0  0  i  0  0  0  0  0 
22  42  AI~  i  l  O  O  O  O  O  O  O 
Thr  19  i~  0  0  0  0  0  3  1 
Ser  22  O  4  9  5  2  0  0  O 
23  30  Cys  30  9  3  4  5  2  0  3  i 
24  26  Arg  ii  1  3  4  O  0  0  O  0 
Thr  2  O  O  O  O  2  O  O  O 
8er  6  0  0  0  &  0  O  2  0 
Gly  i  00  0  O  0  0  i  0 
Gln  4  3  0  O  O  O  O  O  i 
Glx  2  2  O  0  O  O  O  0  O 
25  25  Ala  13  6  O  4  O  O  0  O  O 
8er  2  0  2  0  0  0  0  0  O 
oly  3_o  o  o  o  4  2  o  3  z 
26  24  Thr  2  O  O  O  O  2  0  O  O 
Ser  16  6  2  4  i  0  0  0  O 
Gly  2  O  O  O  200  O  O 
Asp  4  0  O  O  O  0  0  3  i 
0  0 
0  0 
0  0 
i  i 
0  0 
0  i 
0  0 
0  0 
I  i 
0  l 
O  0 
0  0 
0  0 
0  0 
0  i 
I  i 
0  i 
i  i 
0  0 
O  0 
1  0 
0  2 
i  2 
i  2 
0  0 
0  0 
0  0 
0  0 
0  0 
i  2 
0  0 
O  O 
0  0 
i  2 
0  0 
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TABLE  l--Continued 
No.  of 
Position  ~otein  ~inOTotalH~nKapp  a  H~anL~bda  MouseK~pa 
Sequences  Acids  III  IIl  III  Ill IV  V  I  II 
Studied 
23  ~s  i  000  00010  O0 
Ser  5  000  31001  O0 
Asn  i  000  00010  O0 
Glu  i  000  00010  O0 
Gln  13  5  i  4  0  0  0  0  0  1  2 
G~  2  i  i  0  0  0  0  0  0  0  0 
a  22  Ser  5  0  i  3  0  0  0  0  0  0  i 
Asn  i  010  00000  O0 
---  ~  601  31021  ii 
b  22  ~u  2  020  000  00  00 
Val  i  000  00000  Of 
---  ~  604  31021  ii 
c  22  Leu  2  020  000  00  0  0 
---  20  604  31021  12 
d  22  T~  i  000  i0000  00 
Ser  3  000  21000  00 
Asp  i  010  00000  O0 
---  ~  614  000  21  i  2 
e  22  Asp  2  010  010  00  0  0 
Asn  3  000  30000  00 
Asx  i  O00  00000  Of 
---  ~  614  000  21  1  1 
f  22  Val  2  001  010  O0  0  0 
Set  2  O10  00000  Of 
G~  i  000  i0000  O0 
G~  i  o  i  o  o  o  o  o  o  o  o 
---  16  603  20021  ii 
28  22  Ile  i  000  i  00  00  0  0 
~u  4  001  00021  O0 
Val  2  002  00000  O0 
Met  i  000  i0000  O0 
i  000  10000  O0 
Set  3  iii  00000  00 
Gly  2  010  010  00  0  0 
His  i  000  00000  01 
Asp  4  400  00000  00 
Asx  3  i00  00000  ii 220  BENCE  JONES  PROTEINS  AND  ]~{YELOMA  LIGHT  CHAINS 
TABLE I--Continued 
Position 
3o 
31 
32 
33 
34 
No.  of 
Protein  Amino  Total  Human Kappa  Human Lambda 
Sequences  Acids  III  IIl  I II Ill IV  V 
Studied 
21  lie  8  600  00000 
~g  2  001  000  Ol 
Ser  3  003  00000 
G~  4  000  20010 
G~  i  000  00010 
Asp  i  010  00000 
Asx  2  010  010  00 
21  lle  2  i00  00000 
~s  2  i00  00010 
Set  2  i00  00000 
G~  5  021  00001 
Asp  i  000  00010 
Asn  8  303  20000 
Asx  I  000  010  O0 
20  ~  i  000  00001 
Phe  i  000  00010 
~s  2  i00  01000 
T~  2  ii0  00000 
Ser  7  102  20000 
His  i  i00  00000 
Ash  4  102  00000 
Asx  2  ii0  00000 
20  Trp  i  i00  000  O0 
I0  223  21000 
Phe  5  301  00000 
Leu  1  000  00000 
T~  1  000  00010 
Asp  i  000  00001 
Ash  i  000  00000 
Leu  Ii  424  00000 
Val  4  000  210  i0 
Met  i  000  00000 
Ala  i  000  00001 
Ser  i  000  00000 
~  i  000  i0000 
Ala  6  i0~  00001 
Ser  3  000  ii0  i0 
Asp  i  010  00000 
Ash  4  210  000  O0 
Asx  3  i00  00000 
Mouse Kappa 
I  II 
i  i 
0  0 
0  0 
0  i 
0  0 
0  0 
0  0 
0  1 
0  0 
0  1 
i  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
i  i 
0  0 
0  i 
0  0 
0  0 
0  0 
0  i 
i  0 
0  0 
0  0 
0  i 
0  i 
0  0 
0  i 
0  0 
i  0 
0  0 
0  0 
0  0 
0  0 
0  i 
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TABLE  1--Continued 
No.  of 
Protein  Amino  Human Kappa  Position  Total 
Sequences  Acids  III  III 
Studied 
35  17  Trp  17  42  4 
36  17  Tyr  13  424 
Phe  2  0  0  0 
Leu  i  0  O  O 
His  i  O  O  O 
37  16  Leu  2  020 
Gln  12  3  0  4 
Glx  2  0  O  0 
38  16  His  I  000 
Gin  12  3  i  4 
Glx  3  0  i  O 
39  16  Leu  2  0  0  0 
Lys  9  223 
Arg  ~  0  0  i 
Gly  l  1  0  0 
His  i  0  0  0 
Asx  I  0  0  0 
40  16  Pro  15  3  i  4 
Ala  i  0  1  0 
41  16  I~s  i  i  0  0 
Gly  15  2  2  4 
42  16  Lys  3  30  0 
/krg  i  0  0  0 
Thr  2  00  0 
Gin  7  0  1  4 
Glx  3  0  10 
43  16  Pro  i  00  0 
Ala  ii  3  0  4 
Thr  i  O  O  0 
Ser  2  0  i  O 
Gln  i  0  i  O 
41~  16  lle  i  0  0  0 
Pro  15  3  2  4 
45  16  Leu  2  0  0  0 
Lys  9  3  0  i 
A~g  3  0  0  3 
Ser  i  0  i  0 
Glx  1  0  1  0 
Human Lambda  Mouse Kappa 
I II iII IV  V  I  II 
210  ii  1  1 
ii001  O0 
OOOlO  O1 
00000  i0 
i  0  0  0  0  0  0 
O  0  0  O  O  0  0 
2  i  0  i  i  0  O 
O0000  ii 
i0000  0  0 
ii0  ii  O0 
00000  ii 
200  O0  0  0 
000  Ol  0  i 
OOOlO  O  O 
00000  O0 
010  O0  O  O 
00000  i0 
210  ii  i  i 
00000  O0 
000  O0  00 
210  ii  ii 
00000  O0 
O10  O0  O0 
20000  O  O 
O0011  O  O 
00000  ii 
000  O0  0  i 
21001  O  O 
O0000  i0 
00010  O0 
00OO0  O  O 
O00OO  i0 
210  ii  0  i 
00011  O  O 
21000  i  i 
00000  O  O 
00000  O0 
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TABLE  I---Continual 
Position 
~6 
47 
48 
49 
9o 
51 
52 
53 
54 
No.  of 
P~'otein  Amino  Total 
Sequences  Acids 
Studied 
14  Ile  i 
Leu  12 
Arg  i 
14  Izau  ii 
Val  3 
14  lle  12 
Met  2 
14  Tyr  13 
Phe  I 
14  Leu  i 
Val  i 
Lys  i 
Ala  2 
Arg  i 
Thr  i 
Set  i 
ol~  3 
Asp  2 
Glu  1 
14  Leu  1 
Val  2 
Ala  5 
Arg  i 
Thr  i 
Gly  i 
Hi  s  1 
Asp  2 
14  Ser  i0 
Asp  1 
Asn  2 
Glu  i 
~s  3 
Set  4 
Asn  4 
Glu  i 
Glx  1 
lb.  Leu  4 
irg  9 
Gln  1 
Human Kappa  Human Lambda  Mouse Kappa 
I II IIl  III  III IV  V  I  II 
i00  00000  00 
222  21011  01 
000  00000  i0 
322  20000  ii 
000  01011  00 
221  210  ii  i  i 
I01  000  00  0  0 
322  20011  ii 
000  01000  O0 
010  000  O0  0  0 
001  00000  00 
i00  00000  0  0 
000  00000  i  I 
000  lO000  O0 
010  00000  O0 
000  00010  O0 
001  01001  O0 
200  00000  00 
000  100  00  0  0 
010  000  O0  0  0 
001  01000  O0 
301  00000  Of 
000  00001  O0 
000  00000  i0 
OlO  000  O0  O0 
000  00010  O0 
000  20000  O0 
322  01000  ii 
000  i0000  O0 
000  i0001  O0 
000  000  i0  0  0 
010  00000  O0 
ZOO  20000  O0 
102  00000  i0 
llO  O0001  O1 
000  01000  O0 
000  000  i0  O0 
300  00000  l  O 
022  21011  O0 
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TABLE  I--Continued 
No.  of 
Protein  Amino  Position  Total  Sequences  Acids 
Studied 
5~  16  Pro  5 
Ala  6 
Gly  i 
Asx  i 
GIu  3 
56  16  Ala  i 
Thr  5 
Ser  i0 
57  ~6  Thr  l 
GIF  15 
58  16  lle  6 
Val  9 
Thr  1 
59  16  Pro  16 
60  16  Val  1 
Lys  i 
Ala  1 
Ser  3 
Asp  8 
Asn  i 
GIu  i 
61  16  Arg  16 
62  16  lle  i 
Phe  15 
63  16  lle  I 
Ser  15 
64  16  Ala  i 
Oly  15 
65  16  Thr  i 
Set  15 
66  16  Lys  3 
Arg  i 
8er  2 
Gly  i0 
67  16  Phe  i 
Set  15 
Human Kappa  Human Lambda  Mouse Kappa 
I II Ill  I II llI IV  V  I  II 
000  21011  O0 
024  00000  O0 
000  00000  O  l 
000  00000  i0 
3OO  00000  O0 
i00  00000  O0 
104  00000  O0 
120  210  ii  i  i 
000  00010  O0 
324  21001  ii 
003  i00  ii  0  0 
320  ii000  ii 
001  00000  0  0 
24  210  I  1  i  l 
OO1  00000  O0 
000  00000  i0 
000  00000  O1 
300  00000  O0 
013  21001  O0 
010  00000  O0 
000  00010  O0 
324  21011  Ii 
000  i0000  00 
324  ii011  ii 
i00  00000  O0 
224  21011  l  l 
000  i00  O0  O0 
324  ii0  ii  i  i 
i00  000  00  0  0 
224  21011  l  l 
000  21000  0  0 
000  00000  i0 
000  O0011  O0 
324  00000  Of 
lO0  00000  O0 
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TABLE  I--Continue~ 
NO.  of 
Protein  Amino  Human Kappa 
Position  Total  Sequences  Acids  III  IIl 
Studied 
68  16  Gly  15  324 
Asn  I  O  O  0 
69  16  Ala  2  001 
Thr  ii  323 
Sel  i  0  0  0 
His  i  0  0  0 
Asp  i  0  0  0 
70  16  Thr  3  0  0  0 
Set  2  0  0  0 
Asp  9  2  i  4 
Asx  i  O  i  O 
GIu  i  i  O  0 
71  16  Tyr  i  O  O  0 
Phe  i0  3  2  4 
Ala  5  O  O  O 
72  16  Thr  Ii  3  2 
Ser  5  O  0  0 
73  16  Phe  2  200 
Leu  14  i  2  )4 
74  16  Lys  i  O  i  0 
Ala  i  0  0  0 
Thr  12  31 
Oly  .  i  000 
Asn  1  0  0  0 
75  16  Ile  15  32  4 
Val  1  0  0  0 
76  16  Thr  2  000 
Ser  13  3  2  4 
His  1  0  0  0 
77  17  Pro  i  0  0  0 
Arg  6  O  2  )4 
Ser  )4  3  0  0 
Gly  6  i  O  O 
78  17  Leu  13  )4  1  /~ 
Val  i  0  i  0 
Met  i  O  0  0 
Ala  2  0  0  O 
Human Lambda  Mouse Kappa 
! II III IV  V  I  II 
20011  ii 
OlO00  O0 
00010  O0 
20000  Of 
00000  i0 
00001  O0 
O1000  O0 
010  ii  O0 
20000  O  O 
00OOO  ii 
OOO00  O0 
000  O0  0  O 
O0000  i0 
000  O0  0  i 
21011  O0 
lOOlO  O0 
llO  O1  l  l 
OO0  OO  O0 
210  ii  i  i 
00000  O0 
i0000  O0 
01011  i0 
i0000  O0 
00000  O  l 
20011  ii 
01OO0  O0 
i00  Ol  O0 
ii0  i0  1  0 
00000  Of 
00000  O  l 
O0000  O0 
00000  i0 
21011  O0 
21000  i0 
000  O0  0  0 
0OOO0  O  i 
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TABLE  I--Continued 
No.  of 
Protein  Amino  Human Kappa  Human Lambda  Mouse Kappa  Position  Total 
Sequences  Acids  III  III  III  III IV  V  I  II 
Studied 
79  17  Arg  3  0  O  0  2  i  0  0  0 
Glu  5  0  i  3  0  O  0  0  0 
Gln  6  4  0  0  0  0  0  i  i 
Glx  3  0  1  1  0  0  O  0  0 
80  i  7  Pro  9  15  i  4  0  0  0  0  0 
Ala  3  0  i  0  0  i  0  0  i 
Thr  i  0  0  0  i  0  0  0  0 
Set  3  0  0  0  I  0  0  i  0 
Glx  1  0  0  0  0  0  0  0  0 
81  17  V&l  1  0  0  0  0  0  0  1  0 
Ala  1  1  0  0  0  0  0  0  0 
Gly  1  0  0  0  1  0  0  0  0 
Asp  1  1  0  0  0  0  0  0  0 
Asx  i  0  0  0  0  0  0  0  0 
G!u  i0  2  i  4  I  0  0  0  i 
Glx  2  0  1  0  0  1  0  0  0 
82  17  Asp  14  4  l  4  2  0  0  l  l 
Asx  3  0  i  0  0  i  0  0  0 
83  18  Ile  2  2  O  0  0  0  0  0  0 
Phe  8  2  i  4  0  0  0  0  0 
Val  i  0  i  0  0  0  0  0  0 
Thr  i  0  0  0  0  0  0  0  0 
Glu  5  0  0  0  2  0  0  2  i 
Glx  I  0  0  0  0  i  0  0  0 
84  18  Val  1  0  0  0  0  0  0  0  0 
Aim  16  4  I  4  2  i  0  2  i 
Gly  i  0  1  0  0  0  0  0  0 
85  18  Val  6  0  2  4  0  0  0  0  0 
Met  i  0  0  0  0  0  0  0  0 
Thr  4  4  0  0  0  0  0  0  0 
His  i  0  O  0  i  0  0  0  0 
Asp  5  0  0  0  i  0  0  2  i 
Asx  i  0  0  0  0  I  0  0  0 
86  20  Tyr  20  6  2  4  2  i  0  2  i 
87  20  Tyr  16  6  2  3  2  1  0  i  l 
Phe  3  0  0  1  0  0  0  i  0 
His  i  0  0  0  i  0  0  0  0 
88  21  Cys  21  6  2  4  3  i  0  2  i 
0  0 
i  0 
0  0 
0  3. 
0  0 
0  0 
0  0 
i  0 
0  i 
0  0 
0  0 
0  0 
0  0 
0  i 
3_  0 
0  0 
i  0 
0  i 
0  0 
i  0 
0  0 
0  1 
0  0 
0  0 
i  0 
0  i 
0  0 
0  0 
0  i 
0  0 
0  O 
i  0 
0  0 
i  i 
0  0 
0  i 
0  0 
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TABLE  I--Contlnued 
position 
89 
9o 
91 
92 
93 
94 
No.  of 
Protein  Amino  Total  Human Kappa 
Sequences  Acids  III  llI 
Studied 
Human Lambda  Mouse Kappa 
I II Ill IV  V  I  II 
22  Leu  I  000  00000  i0 
Met  i  010  00000  00 
Ala  2  000  20000  00 
8er  1  000  01000  00 
Asn  I  000  00001  00 
Gin  ~  624  10020  O0 
Glx  i  O00  00000  01 
22  Met  i  010  OOOO0  O0 
Ala  3  000  200  lO  O0 
T~  2  000  i0010  O0 
Set  2  000  01001  00 
Gin  13  622  00000  iO 
Glx  1  000  00000  01 
22  Trp  5  000  30020  O0 
~r  12  51~  0"i000  i0 
Phe  i  i00  00000  00 
Ala  1  010  00000  00 
Arg  2  010  00001  O0 
Set  I  000  00000  O  l 
21  Leu  2  020  00000  O0 
Val  i  000  O10  O0  00 
~s  i  000  00000  Of 
Ala  i  000  00000  i0 
G~  3  00  3  O  00  O  O  O  0 
Asp  9  400  20021  O0 
ASh  i  i00  OO000  O  O 
GIu  3  Iii  00000  00 
21  ~  1  000  i0000  00 
T~  4  111  00010  00 
Ser  7  102  i0011  i0 
Gly  i  001  00000  O0 
His  i  L00  00000  00 
Asp  i  i00  00000  00 
Ash  2  200  00000  O  O 
Asx  i  000  O1000  O0 
GIu  2  010  00000  01 
Gin  i  010  00000  O0 
21  Ile  2  010  00010  O0 
Leu  5  500  00000  00 
Val  i  000  00000  Of 
Met  i  OOO  O0010  00 
Ala  i  010  00000  O0 
~g  i  000  i0000  O0 
Ser  8  014  i0001  iO 
Asp  i  iO0  00OOO  O0 
Asx  i  O00  01OO0  O0 TAI  TE  WU  AND  ELVIN  A.  KABAT  227 
TABLE I--Continued 
NO.  Of 
Protein  Amino  Human Kappa  Position  Total 
Sequences  Acids  III  III 
Studied 
95  21  Pro  14  5  3  4 
Leu  2  O  0  O 
Thr  i  0  0  0 
Ser  2  i  0  0 
Gly  I  0  00 
Asx  i  0  O  O 
96  21  Trp  2  0  O  O 
Ile  i  O  i  O 
Tyr  2  i  10 
Phe  2  i  0  i 
Pro  I  i  0  0 
Leu  2  i  i  O 
Lys  2  i  00 
Arg  i  i  0  O 
Thr  i  0  0  1 
Set  2  0  O  i 
Ash  i  O  0  0 
Asx  I  0  0  0 
Gin  i  O  0  i 
---  2  0  0  0 
97  20  Phe  l  O  0  0 
Pro  i  0  0  i 
Met  1  1  0  0 
Ala  2  0  0  O 
Thr  12  4  3  3 
His  i  0  0  0 
---  2  O  0  O 
a  19  Val  4  O  0  O 
Ala  i  0  0  O 
---  14  5  3  4 
b  20  lle  i  O  O  0 
Leu  i  O  O  0 
Val  4  O  0  0 
---  i4  5  3  4. 
98  20  Phe  20  5  3  4 
99  20  Gly  20  5  3  4 
i00  20  Pro  i  i  O  O 
Gly  ii  2  10 
Gln  8  2  2  4 
iO1  19  Gly  19  4  3  4 
Human L~mbda  Mouse Kappa 
III  llI IV  V  I  II 
OOO00  ii 
20000  O  O 
000  iO  0  O 
O00  iO  0  0 
00001  O  O 
O10  O0  0  O 
00000  i  i 
O0000  O0 
00000  O0 
0OO00  O0 
0OOOO  OO 
O0000  O  O 
00001  O0 
00000  O  O 
00000  O0 
i0000  O  O 
iOOO0  O0 
010  OO  0  0 
000OO  O0 
00020  0  0 
01000  00 
00000  00 
00000  00 
20000  00 
00000  l  l 
00001  00 
00020  O0 
20011  00 
000  l0  0  0 
000  00  i  i 
000  lO  0  0 
00001  00 
210  l0  0  0 
00000  l  l 
2  1  0  2  1  1  1 
2  i  0  2  1  i  i 
00000  O0 
21021  i  i 
00000  O0 
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TABLE  I--Concluded 
No °  Of 
Protein  Amino  Htunan Kappa  Human Lambda  Mouse Kappa 
Position  Total  Sequences  Acids  III  III  III  III IV  V  I  II 
Studied 
102  19  Thr  18  h  3  3  2  1  0  2  i  i  i 
Ser  i  0  0  i  0  0  0  0  0  0  0 
103  19  l~ys  14  4  i  3  i  i  0  i  i  i  i 
Arg  3  0  I  i  0  0  0  i  0  0  0 
Asn  i  0  i  0  0  0  0  0  0  0  O 
Gln  1  0  0  0  i  0  O  0  0  0  0 
104  P_2  Leu  15  3  2  3  i  i  0  2  i  I  i 
Val  7  3  2  i  i  0  0  0  0  0  0 
105  22  Thr  6  0  0  0  2  i  0  2  i  0  0 
Asp  4  3  0  i  0  0  0  0  0  0  0 
Glu  12  3  4  3  0  0  0  0  0  i  i 
106  22  lle  12  3  4  3  0  0  0  0  0  i  i 
Phe  i  i  0  0  0  0  0  0  0  0  0 
Leu  2  i  0  i  0  0  0  0  0  0  0 
Val  7  i  0  0  2  i  0  2  i  0  0 
a  22  Leu  6  0  0  0  2  i  0  2  i  0  0 
---  16  6  4  4  o  o  o  o  o  l  l 
107  22  Lys  15  6  3  4  0  0  0  0  0  i  i 
Arg  3  0  i  0  i  i  0  0  0  0  0 
Set  2  0  0  0  0  0  0  2  0  0  0 
Gly  2  0  0  0  i  0  0  0  i  0  0 
studied at the given position. Only data for which the sequence has been clearly 
assigned by the various authors have been included. 
The Role of Glydne--It has been suggested that glycine plays a unique role 
in  the  structure  of  the  variable  region  of  immunoglobulin  light  chains  (18, 
p. 87; 41-43, 45). Jukes (50) and Welscher (51) have generally agreed with this. 
A  further  careful  analysis  becomes  essential  for  the  understanding  of  the 
function of the glycines in the over-all structure  and in relation to antibody- 
combining sites. 
The  basic  property  that  differentiates  glycine  from  all  other  amino  acids 
structurally is the absence of a side chain. As a result, glycine can have many 
sterically  allowable  configurations.  This  has  been  verified  experimentally  in 
the case of lysozyme (46,  52)  and tosyl-o~-chymotrypsin  (53).  The two angles, 
and  ~  (54),  which specify  the  conformation  of  the  backbone  of an  amino 
acid have been calculated for each of the amino acids from the known tertiary 
structures  of lysozyme  (46,  52)  and  of  tosyl-o~-chymotrypsin  (53).  A  typical 
plot  of  the  permissible  angles  of  the  glycine  as  compared  with  the  alanine 
residues is shown in Fig.  1. The allowable configurations of alanine are mostly TAI  TE  WU  AND  ELGIN  A.  KABAT  229 
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clustered near  the  a-helical region of lysozyme (Fig.  1 a  and  reference 55), 
while those of glycine are widely distributed.  Comparison with  similar  maps 
for other amino acids in lysozyme also shows them to be more restricted. The 
data for tosyl-a-chymotrypsin also show that glycine may have many more con- 
formations (Fig. 1 b). This unique property of glycine thus may permit relative 
motion of the chains attached to the two ends of the molecule. With immuno- 
TABLE  II 
Frequencies o/Glycine  Residues at Various Positions in the Variable Region of Light Chains 
Position  Human Kappa  Human Lambda  Mouse Kappa  Total 
I  II  III  I  II  III IV  V  I  II 
9  10/15  10/63  16 
13  6/9 2/2 6/6  14/61  23 
16  20/21  4/4  13/13  9/9 2/2 6/6 2/2 3-/1  1/1 2/2  60/61  99 
24  i/3  1/26  4 
25  4/4 2/2  3/3 i/I  10/25  40 
26  2/5  2/24  8 
27f  i/3  1/22 
28  i/2  i/1  2/22  9 
29  2/2  1/2  1/2  ~/21  19 
3o  2/2  1/~  1/1  1/1  5/21  24 
39  V3  V16  6 
41  ~3  2/2  ,+/4  2/2  1/J.  1/1  1/~.  1/1 1/1  15/16  94 
~o  1/2  3./1  ]/1  3/J-~  21 
51  1/2  1/14  7 
~5  1/1  1/16  6 
57  3/3  2/2  4/4  2/2  1/1  1/1  3_/1 3_/1  15/16  94 
614  3/3  2/2  4/4  1/2 i/i  i/i I/i  i/i i/i  15/16  94 
66  3/3  2/2  4/4  l/J_  J_O/l~  ~2 
6~  3/3  2/2  4/4  2/2  1/1  1/1  1/1 3_/1  15/16  94 
74  ~/2  1/~6  6 
77  1/4  2/2  1/1  1/1 1/1  6/17  35 
8~  ~/2  ~/~7  6 
84  1/2  VI~  6 TAI  TE  WU  AND  ELVIN  A.  KABAT 
TABLE II--Concluded 
Position  Human Kappa  Human Lambda  Mouse Kappa  Total 
I  II  III  III  III  IV  V  III 
92  3/4  3/21  14 
93  1/4  1/21  5 
95  i/i  1/21  3 
99  5/5  3,/3  4/4  2/2 i/i  2/2 i/i  i/i 1/i  20/20  i00 
i00  2/3  1/3  2/2  1/1  2/2  1/1  1/1  1/1  11/2o  33 
I01  k/4  3/3  4/4  2/2  1/1  2/2  1/1  t/1  1/l  19/19  I00 
io7  1/2  1/~  2/18  11 
231 
Fractions  represent  the number  of instances  in which glycine  occurs  to the 
total number  of proteins  studied at the given position  for each  subgroup. 
When values  have not been given~  glycine has not been reported  ~t that position 
in the  subgroup. 
globulins,  flexibility of the protein backbone can be one of the major factors 
that  permit  substitution  of various  amino  acids  at  the variable positions;  it 
also may allow movement of the site to make most favorable contact in com- 
bining with an antigenic determinant.  Though a glycine residue confers maxi- 
mum flexibility over all other amino acids, it might also arise from a  random 
mutation in which the difference between glycine and other amino acids is not 
adverse for the  over-all structure.  In  addition,  some glycines might be com- 
plementarity  determining.  These  latter  two  kinds  of  glycines  must  be  dis- 
tinguished from the first. 
For the variable region  of the light chains  of human  and mouse immuno- 
globulins  and  of  Bence  Jones  proteins,  alignment  of  amino  acid  sequences 
serves to identify the glycines which may be conferring flexibility as shown in 
Table II. All  the  glycines are listed.  The frequencies,  expressed as per  cent, 
can roughly be divided into three categories: 
A. 94-100%: Positions 16, 41  (or 39), 57,  64,  68,  99,  and 101.  Since glycine 
occurs  at  these  positions  in  nearly  all  the  proteins  studied,  it  must have  a 
fundamental structural significance and has been preserved in the evolution to 
man  and  mouse.  These  glycines  are  assumed  to  confer  flexibility unique  to 
antibodies. 
It is of interest that glycine occurs at position 41 in 15 of 16 proteins studied 
(94%). The sequence at residues 39, 40,  and 41 is Lys-Pro-Gly in 14 cases and 
Lys-Ala-Gly in one case. In the single exception,  a human nI protein Ag,  the 232  BENCE  JONES  PROTEINS  AND  I~YELOMA  LIGHT CHAINS 
sequence  at 39,  40,  and 41  is  Gly-Pro-Lys.  1 Thus if the reported sequence is 
correct,  the  glycine at  residue  39  might well serve  the  same function  as  the 
glycine  at  position  41.  The  two  positions 41  and  39  may thus  provide  one 
invariant glycine (100%). 
B.  35-62%:  Positions 25,  66,  77,  and  100. A  careful ex~mination indicates 
that glycines at these positions are at least group specific. Thus, within a group 
(K or X), they could serve the same function as the glycines of category A. 
C. 4-24%:  Positions 9,  13,  24,  26,  27f,  28,  29,  30,  50,  51,  55,  74,  81,  84,  92, 
93,  95,  and  107.  These glycine residues are at variable positions.  They there- 
fore play a distinctly different role from those of the other two categories. They 
might either be related to antibody complementarity or, if not involved in the 
site itself,  could have arisen from random mutation and be nevertheless com- 
patible with three-dimensional folding. 
Thus there are about 8 (human K and mouse K) to 10 (human X) glycines in 
the variable region of the light chains of all proteins for which  sequence data 
are available at these positions.  They are as follows: 
Human e: Positions 16, 
Human X: Positions 16, 
Mouse K: Positions 16, 
41 (or 39), 57, 64, 66, 68,  99,  and 101. 
25, 41,  57, 64,  68, 77, 99, 100, and 101. 
41,  57, 64,  68,  99, 100, and 101. 
Positions  99,  100,  and  101  have been postulated  to function  as  a  pivot per- 
mitting  the  combining regions  of  the  light  and  heavy chains  to  make most 
favorable  contact  with  the  antigenic  determinant  (18,  p.  87;  and  41,  43). 
Examination  of  the  heavy chain  sequences  reported  to  date  (56,  57)  shows 
Gly-Gln-Gly at positions  112, 113,  and  114  in  two instances  (He and Daw), 
Gly-Arg-Gly in one (Cor)  and Gly-Gly at positions 114 and 115 in Eu; but in 
the latter protein two gaps have been placed at positions 108 and 109 in align- 
ing with He for maximum homology. Thus these glycines could also be func- 
tionally and positionally equivalent. 
Invariant  Residues--Earlier  comparisons  of  the  invariant  residues  of  the 
variable and constant regions were based entirely on those positions at which 
only  a  single  amino  acid  occurred.  As  more  data  accumulated  this  number 
diminished,  until there are now only 11  such positions in the variable region: 
Gln 6,  Cys 23,  Trp 35,  Pro 59,  Arg 61,  Asp (Asx) 82,  Tyr 86,  Cys 88,  Phe 98, 
Gly 99,  and  Gly 101.  However,  if one  accepts  as essentially invariant  those 
positions at which  more than  88-90%  of the proteins  studied  have the same 
amino acid at a  given position, this number increases to 29.  A  comparison of 
these  residues  with  those  in  the  constant  region  is  given in  Table III. This 
procedure allows for possible errors as well as for the ability of some residues 
to substitute  for others  at  a  given position.  The difference between  the  con- 
1  The sequence of Roy was originally reported as Gly-Pro-Lys but has been changed to 
Lys-Pro-Gly (see references to Roy in sequence data). TAI TE WU  AND  ELVIN A.  KABAT  233 
stant and variable regions is not much different than originally appeared (41) 
except  that  there  is  one  invariant  alanine  and  one  invariant  leucine  in  the 
variable region. However,  the difference between the two regions is still quite 
clear,  the variable  region having in  addition no invariant valine,  lysine,  and 
TABLE  III 
Comparison  of the Invariant Residues of the Variable with those of the Constant Region in Human 
K-,  Human  ~-,  and  Mouse K-Bence Jones  Proteins 
Amino Acid  Variable Region  Constant Region 
Gly  7"  O 
Ala  I  3 
Leu  i  3 
Val  0  3 
Lys  0  2 
His  O  2 
lle  i  0 
Ser  3  5 
Glu  0 
Gln  2  0 
Arg  i  0 
Pro  3 
Tyr  2  3 
Cys  2  3 
Phe  2  2 
Trp  i  i 
Thr  2  i 
Asp  i  l 
Total  29  35 
* Not including positions 25, 66, 77, and  100. 
Invariant residues  are those in which 88-90%  of the proteins analyzed contain the same 
amino acid residue at a given position. 
histidine,  while  the  invariant  residues  in  the  constant  region  include  three 
alanines,  three leucines, three valines,  two lysines,  and two histidines. 
Hydrophobicity  Distribution  of the Invariant Residues o/the Variable Region-- 
A  parameter,  H~)  ....  based on the free energies  of transfer of amino acid side 
chains from  an  organic  to  an  aqueous environment has  been  introduced by 
Tanford  (58)  and  applied  by Bigelow  (59)  to  the study  of  various  proteins. 
HO~ve is expressed in kilocalories per residue  and varies from 3.00 for Trp to 
0.45 for Thr and is very small,  zero,  or negative for Gly,  Ser,  His,  Asp,  Glu, 
Asn, and Gln; these have been taken as zero. These values have been used in 234  BENCE  JONES  PROTEINS  AND  MYELOMA  LIGHT  CHAINS 
an examination of the invariant residues of the variable region.  Table IV sum- 
marizes the findings and tabulates H0~v, for the invariant residues and for the 
occasional other substituents found. In addition we have included data on two 
positions, 46 and 48, in which another substituent occurred with slightly lower 
frequency than that required by the definition of an invariant residue,  and on 
three other positions 8,  12,  and 37 in which  the other substituents  were con- 
fined to a single subgroup. 
TABLE  IV 
Hydrophobicity, HO  ..... of the Invariant Residues  and almost Invariant Residues of the 
Variable Region 
Amino Acids  Hydrophobicity,  H~ave 
Position  Invariant  Other  Invariant  Other 
.5  Thr 67*  Ala 2~  Ser i  0.45  0.75, O.00 
6  Gin 63  0.O0 
16  Gly 60  Arg i  0.00  0.75 
23  Cys 30  1.00 
35  Trp 17  3.  O0 
35  Gin 12, Glx 3  His i  O.00  0.00 
40  Pro 15  Ala 1  2.60  0.75 
41(39)  sly 15  Lys i  0.00  1.50 
44  Pro 15  Ile i  2.60  2.95 
49  Tyr 13  Phe i  2.89  2.65 
57  G<v 15  Thr 2  0.OO  0.~5 
59  Pro 16  2.60 
61  Arg 16  0-75 
62  Phe 15  Ile i  2,65  2-95 
63  Ser 15  lie i  O.OO  2.95 
64  Gly 15  Ala i  0.00  O.75 
65  Ser 15  Tkar i  0.  O0  O 45 
67  Set 15  Phe i  0 O0  2.65 
68  Gly 15  Ash i  O.  O0  0.00 
73  Leu 14  Phe 2  2.40  2.65 
75  lle 15  Val i  2.95  1.70 
$2  Asp 14, Asx 3  O.  OO 
64  Ala 16  Gly i~ Val i  0.75  0.00~  1.70 
86  Tyr 20  2.85 
88  Cys 21  i.  O0 
98  Phe 20  2.65 
99  G!y 20  O.  O0 
lOl  Gly 19  O.  O0 
102  Thr 16  Ser i  O.  45  O.  OO TAI TE  WU AND ELVIN A.  KABAT 
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Position 
46 
48 
Position 
8 
12 
Borderline  for almost invariant. 
Amino Acids  Hydrophobicity~  H~ave 
Invariant  Other  Invariant  Other 
Leu 12  lle i, Arg i  2.40  2-95, 0 75 
lle 12  Met 2  2.95  1.30 
Invariant with a subgroup exception. 
Amino Acids  Hydrophobicity,  H~ave 
Invariant  Other  Invariant  Other 
Pro 58  Ala 6  2.60  0.75 
(Human X III) 
Ser 56  Pro 4  0.00  2.60 
(Human ~ II) 
Ala i  0.75 
(Mouse ~ II) 
Giu 12, Glx 2  Pro 2  0.00  2.60 
(Human  ~ II) 
* Numbers next to the residue represent the number of samples in which the 
residue occurred. 
It is of interest that 15 of the invariant residues have values of 0.00 or 0.45 
and that  10 have values of 2.40-3.00,  leaving only 4  residues of intermediate 
hydr0phobicity: 2 half-cystines, 1 arginine, and 1 alanine. In most instances the 
other  substituents  reported  as replacements at  these  positions  generally had 
H0~ve values not too different from the major substituent, but at positions 40, 
41,  63, 67, 75, and 84 changes of over one unit were seen. (Position 41 may not 
be significant since,  as discussed earlier, the exception had glycine in position 
39.)  The two borderline invariant residues both showed substantial H0~ve dif- 
ferences and  the  three  subgroup specific residues  also varied substantially in 
I-I¢~  .... 
Of the 35  invariant residues in the constant region,  11  have values of 0.00 
or 0.45,  13 have values of 2.40 to 3.00,  and 11 have values of 0.75 to 1.70 (Table 
V). Thus the constant region has invariant residues which  appear to be rela- 
tively uniformly distributed with respect to H0,ve while in the variable region 
they are generally either very high or zero. 
The average hydrophobicity for invariant residues of the variable region is 
about 1.09 while that of invariant residues of the constant region is 1.39. 
Welcher  (51)  has computed HOavo for the entire light chain from sequence 
data on Bence Jones proteins and obtains values ranging from 0.970  to  1.04 
kcal/residue, values in the same range as those for chains of other proteins. The 
variable regions range from 0.930 to 1.11 while the constant region values were 236  BENCE  JONES  PROTEINS  AND  MYELOMA  LIGHT  CHAINS 
0.950 for mouse K, 0.970 for human K, and  1.02 for human X. Thus the over-all 
hydrophobicities of the two regions are no different; Welcher also reported no 
difference  between  the  two  regions  with  respect  to  the  pattern  of  nonpolar 
positions, while our data show a substantial difference in H0~w of the invariant 
residues of the two regions. Moreover, the average hydrophobicity of the entire 
TABLE V 
HydrophoMcity, HO~T~, ~  the Invarlant  ResCues ~  the Constant Region 
Position  Amino  Hydrophobicity  Position  Amino  Ilydrophobicity 
Acid  H~ave  Acid  H~ave 
iii  Ala  O.7~  149  Lys  1.50 
112  Ala  0.75  151  Asp  O.OO 
113  Pro  2.60  168  Ser  O.OO 
i15  va2  1.7o  173  Tyr  2.85 
118  Phe  2.65  176  Ser  O.OO 
119  Pro  2.60  177  Ser  O.OO 
120  Pro  2.60  179  Leu  2.40 
121  Set  O.00  181  Leu  2.40 
123  Glu  O.OO  189  His  O.  O0 
125  Leu  2.40  192  Tyr  2.85 
130  Ala  0.75  194  Cys  i.O0 
133  Val  1.70  197  Thr  0.45 
134  Cys  i.  OO  198  His  O.  OO 
139  Phe  2.65  203  Ser  0.00 
140  Tyr  2.85  207  Lys  1.50 
141  Pro  2.60  213  Glu  O.OO 
146  Val  1.70  214  Cys  i.  OO 
14S  Trp  3.OO 
constant region is  about 0.98,  significantly lower than  1.39 for the hydropho- 
bicity of its invariant residues. 
Variability--In  considering the nature of the variable region, it is of impor- 
tance to ascertain whether the variability is uniformly distributed or is confined 
to small segments of the variable regions. Thus,  a  quantity is defined for each 
amino acid position in the sequence 
Number of different amino acids at a given position 
Variability  =  Frequency of the most common amino acid at that position  [1] 
in which the denominator is the number of times the most common amino acid 
occurs divided  by the  total number  of proteins  examined.  Thus at position  7 
(Table  I)  63  proteins  were  studied,  serine  occurred 41  times  and  4  different TAI  TE  WU  AND  ELVIN  A.  KABAT  237 
amino acids, Pro, Thr, Ser, and Asp, have been reported. The frequency of the 
most common is 41/63  =  0.65 and the variability is then 4/0.65  =  6.15.  When 
there was uncertainty as to the number of amino acids, as in instances in which 
Glx or Asx has been reported, the extreme values of variability have been com- 
puted. For this equation an absolutely invariant residue would have a value of 
1 while the theoretical upper limit for 20 amino acids randomly occurring would 
be 400. 
150  ~  I  [  I  I 
i00 
GAP  °i 
O  '1  [  I 
25  50  75  100 
Position 
FIG. 2. Variability at different amino acid positions for the variable region of the light 
chains. GAP indicates positions at which insertions have been found. 
Plotting  variability  against  position  for  the  107  residues  of  the  variable 
region (Fig. 2) shows three main peaks in the regions of residues 28, 50, and 96; 
two of these, 28 and 96,  are the highly variable regions (7, 45, 47, 49) in which 
insertions occur,  while position 50 has not been associated with an insertion. 
Fran~k (49)  has previously noted the high variability around position 50.  The 
stretches of amino acid residues showing this high variability are 24-34, 50-56, 
and  89-97.  The first and  third  regions begin after an invariant  Cys and  are 
followed by an invariant Trp and Phe respectively, at positions 35 and 98. The 
second region  begins  after  an  almost invariant position 49  (Tyr  13/14,  Phe 
1/14) and is followed by an invariant position 57 (Gly 15/16, Thr 1/16)  (Table 
I). 
The over-all sequence data were also examined to ascertain whether  amino 
acid substitutions at each position were reflected in changes in hydrophobicity 238  BENCE  JONES  PROTEINS  AND  MYELOMA  LIGHT  CHAINS 
confined to certain stretches of the variable region. The findings which are not 
plotted  showed  that  the  same  three  regions  associated  with  high  variability 
were those with the greatest variation in H 0 .... 
Since a  portion  of the variability at many positions is group- or subgroup- 
specific and is therefore generally not complementarity determining, variability 
as defined in equation [1] was computed for the individual subgroups for which 
sufficient sequence data were available. A plot for KI showed high variability in 
the stretches 24-34 and 92-96 and at residues 53 and 56.  KIII shows high vari- 
ability at residue  96.  Data  are generally insufficient  even for these  two  sub- 
groups and the data for other subgroups do not permit such an analysis;  the 
M  subgroup showed unusually high variability at position 18. 
Classification  of Variability at Individual Positions--The sequence data avail- 
able  at  each  position  (Table I)  were  examined  in  an  attempt  to  classify the 
position  with  respect  to its  role  in  the  over-all structure.  Invariant residues 
already  considered  are  not  included.  The  following  categories  were  set  up. 
(a) Invariant except for one subgroup.  (b) K- vs. X-specific.  (c) K- vs. X-specific 
with some subgroup variations. (d)  Variation in K- and X-subgroups. (e) Varia- 
tion  in  d-subgroups  with  X relatively constant.  (f)  Variation  in  X-subgroups 
with K relatively constant.  (g) Unaccountable variability. (h) Insufficient data. 
(i)  Possible  species  specificity.  It  has  not  been  possible  to  set  up  absolute 
criteria for each of these classes and some difficulties were encountered in mak- 
ing these assignments, especially at positions for which the sequence data were 
relatively  sparse.  Occasional  substitutions  compatible  with  point  mutations 
have often been neglected. 
Examinations of each of these categories permit some interesting inferences 
to be made: 
(a)  There are five positions,  8,  12,  15,  37,  and 54,  which  are essentially in- 
variant except that in one subgroup another amino acid occurs. Thus at position 
8, 58 proteins have Pro while 6, all of which belong to the MII subgroup, con- 
tain  Ala.  At  the  other  positions,  additional  amino  acids  sometimes occur  in 
individual  proteins.  These  positions  are  considered  to  be  part  of  the  basic 
skeleton of the variable region under the control of structural  genes,  the sub- 
group differences being the result of permissible mutations. 
(b)  Six  positions,  7,  33,  71,  83,  105,  and  106,  show  predominantly  K- vs. 
X-specificity. Thus at position 7, 41  human K- and mouse d-proteins have Ser 
while  20  human  X-specimens have Pro.  Two exceptions  occur,  a  nII protein 
with Thr instead of Ser, and a XV with Asp instead of Pro. 
(c)  At five additional positions, 1, 2, 13, 25, and 27, evidence of K- vs. X-speci- 
ficity persists but a substitution may occur in one or more subgroups. Thus at 
position  1,  16 human X-proteins of subgroups M,  MI, MII have PCA,  while 
MV and XV have no amino acid, and 31 human and mouse KI and ~II proteins 
have Asp  (5  additional  have Asx)  while  14  human  KIII specimens have  Glu TAI  TE  WU  AND  ELVIN  A.  KABAT  239 
(1 additional with Glx). There are several exceptions: one human rlII with Lys 
and one with Asp and one mouse rII with PCA. 
The 11 positions in categories 3 and c are of importance because they show 
that r- and X-specificity is not exclusively a property of the constant region but 
involves the variable region as well. These findings are consistent with the data 
indicating that the variable and constant regions of r-chains always go together 
as do the variable and constant regions of X-chains.  They are also in accord with 
the  immunochemical studies  of Ruffilli and  Baglioni  (60)  who  showed  that 
X-specificity extended into the variable region, and with those of Ruffilli (61) 
that determinants in the variable region of K cross-react with anti X-sera. They 
also suggest a continuous evolutionary association for the variable and constant 
regions of the K-chains as well as for the variable and constant regions of the 
X-chains.  The regions showing K- and X-specificity appear to be distributed at 
the beginning and end of the variable region. 
(d-f)  These three categories are instances of variation in composition ascrib- 
able to subgroup variation. At 9  positions, 3,  14, 18, 19, 22, 29, 42, 51, and 79, 
variation ascribable to subgroups is seen in both K  and X chains. In an additional 
10 positions, 4, 9,  10, 17, 20, 21, 55, 56,  77, and 85, subgroup variation is pre- 
dominantly in K-chains with X relatively constant, and'at  15 positions, 11, 26, 
39,  47,  52,  66,  69,  72,  76,  78,  80,  89,  95,  97,  and  107, the subgroup variation 
seems  to  involve X-chains  with  K relatively constant.  The larger number  of 
residues placed in category f  is probably a consequence of the classification of 
X-chains into five subgroups  while  K-chains  are  only divided into  three sub- 
groups. Moreover the number of samples of X-chains is fewer than for K-chains 
so that other types of variation may be masked. 
(g)  Unaccountable variability. At 8 positions, 28, 30-32, 93, 94, 96, and  103, 
the variation within each subgroup appears to be greater than can be accounted 
for on any known basis,  especially for those subgroups for which a  sufficient 
number of samples have been examined. It is of interest that except for residue 
103 these positions are clustered in the two regions of highest variability (45) 
and would be brought into close proximity by the disulfide bond I23-II8,. It is 
postulated that these residues may be complementarity determining and actu- 
ally  be  involved  in  making  contact  with  the  antigenic  determinant.  These 
residues are also very close to the position at which insertions occur (Table I). 
(h)  Insufficient data.  At 15  positions, 24,  34,  36, 43,  45,  53,  58,  70,  74,  81, 
87, 90-92, and 104, not enough sequences are available to assign them clearly 
to one of the other categories. Five of the residues, 24, 34, 90  92, occur in  the 
two regions of highest variability close to most of those with  unaccountable 
variability. The others are fairly well spread and only one, 53,  occurs in the 
third highly variable region. Position 18, although placed in group d shows an 
extraordinary variability in the M  subgroup. 
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Jones proteins examined have residues which do not correspond to any reported 
for the human proteins. Thus these two positions are still classifiable as species- 
specific.  Position  96,  with  its  extraordinary  variability,  although  placed  in 
category g might also technically be called species specific since the two mouse 
samples both contain Trp which is absent in the human samples. At all three 
positions  the  human  proteins  show  substantial  variability in  the  number  of 
substitutions  which  can  occur--9  at position 50,  5  at position 60,  and  l l  at 
position 96.  It thus seems very unlikely that the apparent species specificity of 
these positions will persist when more mouse sequences are available. 
DISCUSSION 
The ability to subject the large amount of sequence data on human and mouse 
Bence Jones proteins and light chains to a statistical analysis has supported the 
earlier conclusion  about the  lack of species specificity in  the variable regions 
of human and mouse Bence Jones proteins (40).  The data now available indi- 
cate at most 2 or 3 such residues in the variable region as compared with 36 
in the constant region. Data in other species, although limited to the first few 
amino  terminal  residues,  tend  to  support  this.  The  rabbit  has  always  been 
considered  an  important  exception  to  the  view  that  there  was  little  if  any 
species specificity in the variable region, since rabbit light chains had Ala and 
Ile as N-terminal residues.  However, the  demonstration by Hood et  al.  (62) 
that  the  N-terminal  sequence  of  a  homogeneous  rabbit  antibody  to  the  C 
carbohydrate of the streptococcus was Ala-Asp-Val-Val-Met-Thr-Glu-Thr-Pro- 
Ala-Ser-Val indicates  that the rabbit has merely added  an N-terminal Ala to 
the N-terminal Asp, the other residues then being essentially similar to those 
in human light chains. Thus the rabbit is not an exception to the basic evolu- 
tionary unity of light chains. 
The data now available (Table II) amply support the earlier suggestions for 
the role of the invariant glycines of the variable region both in conferring flexi~ 
bility  (Fig.  1)  to  permit  substitutions  at  the  variable positions,  and  for  the 
glycines at positions  99  and  101,  together  with  the frequently found  glycine 
at residue  100,  in functioning as a pivot to permit optimM fitting around the 
antigenic determinant (18, p. 87 ; and 41,43). This postulate is now strongly sup- 
ported by the finding of two glycines in an analogous region of the heavy chain. 
The heavy chain sequences thus far available also indicate that there may be 
other invariant glycines in the variable region (56,  57). 
The data in Table IV show an unusual  distribution of invariant residues in 
the variable region with respect to H0~ve in that, with a few exceptions, these 
residues have either a high or a low or zero value, while H0~v~ values appear to 
be uniformly distributed  throughout the invariant residues of the constant re- 
gion  (Table V).  The  significance  and  structural  implications  of  this  are  not 
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phobicity, which does not differ significantly for the two halves of the chain 
(51). 
The variability at  each position shows  that  variability is  concentrated in 
three regions of the molecule (49), of which two have also been noted by other 
workers (7, 45, 47). Examination of the basis for the variability at each position 
shows that variation ascribable to K  and X or to their subgroups does not readily 
explain all of the variation. Seven of the eight positions at which the variability 
cannot be otherwise accounted for occur in  two  of these regions.  Of  the  15 
positions for which sufficient sequence data were lacking to permit clear assign- 
ment,  5  occur in  the same  2 regions--24-34 and  89-97  and  those are  the  2 
regions at which additional residues are found (Table I). Much more sequence 
data  will  be required  to  permit unequivocal  elucidation  of  the  role  of  each 
variable position. 
For the moment, if one accepts (a)  the  tendency of the positions of unac- 
countably high variability to be concentrated in the two short stretches of the 
chain at which insertions are found, (b)  the finding that subgroup and group 
specificity occurs in the variable region and indeed probably over substantial 
portions of it, one might formulate the following working hypothesis extending 
the earlier concept (42, 45) : The light chains of immunoglobulins except for the 
regions  of  unaccountable  variability,  24-34  and  89-97,  are  governed  by  a 
number of structural genes, each chain being the product of two linked genes, 
one for the variable and one for the constant region (Hood et al.  in reference 
16).  These structural genes are free to mutate and are limited only by the re- 
quirement that their product be capable of assuming the proper three-dimen- 
sional structure to permit an antibody site to be formed. By hypothesis the 
complementarity-determining residues  are  considered to be  the  result of  the 
insertion into the DNA of the two short  linear sequences, 24-34  and  8%97, 
which specifically determine what kind of antibody site will be formed. In the 
light chain the  two insertions would be brought into close proximity by the 
disulfide bond I2a-IIss. A similar type of insertion would be made in the heavy 
chain,  but  thus far there is  evidence for only one region of high variability 
(56, 57). 
An  insertion  mechanism  involving only short  linear  sequences  provides  a 
substantial  simplification  of  the  problem  of providing  a  seemingly limitless 
number of complementary sites without the use of very large amounts of DNA. 
It would also be more likely to provide the necessary evolutionary stability and 
universality for the antibody-forming mechanism which cannot be adequately 
accounted for by the germ line hypothesis (36)  of one gene for each variable 
region since such a system would diverge on an evolutionary time scale. The 
precision with which the insertion would have to be accomplished, (e.g. changes 
in length of one or two nucleotides would result in nonsense) in itself would tend 
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would completely destroy the ability to form any antibody and individuals with 
such  a  defect  would  probably  not  survive.  It  eliminates  difficulties in  the 
translocation hypothesis which provides for the joining of one of many V genes 
with a  C gene (33)  and yet maintains  the exclusive  association of V, with C, 
and V~ with Cx genes. Indeed the finding that K- and X-specificity extends into 
the variable region supports the concept of one polypeptide chain resulting from 
the action of closely linked V and C genes. This also is consistent with the ai- 
lotypic studies on 3'G, "yM and 3'A  (63-65).  Moreover it has  the  additional 
merit of providing a fixed location for the antibody site while other theories (32, 
34, 35, 39, 66) perrnit it to be formed by different portions of the variable region 
for various antibodies.  Indeed Eisen (16)  considers that  three different sites, 
each of a  different specificity, might be formed by a  given VL and Va pair. 
This  would  make  antibody sites  completely different from  all  other  sets  of 
specific receptors known. The present hypothesis considers the site as involving 
a  small fixed region of the molecule with specificity determined by the differ- 
ences in side  chains  of complementarity-determining residues.  This insertion 
hypothesis  readily  accounts  for  the  variations  in  length  occurring  in  these 
regions; no other hypothesis has  explicitly considered this  or adequately ac- 
counted for it. 
On the basis of this hypothesis which ascribes only a role in three-dimensional 
folding to the first 23 N-terminal amino  acid  residues of the light  chain,  all 
recombinational theories of antibody formation (66, 67) become uninformative 
since they are based exclusively on sequence data in this region and thus are 
probably not dealing with a region involving antibody complementarity. 
The present working hypothesis of linear regions determining antibody com- 
plementarity will stand or fall when adequate numbers of sequences for human 
and mouse light (and heavy) chains have been worked out. 
The hypothesis makes certain predictions which also can be used to test its 
validity. One of these, since the insertion is hypothesized to determine com- 
plementarity,  is  that  antibody molecules of  a  given  specificity and  with  a 
uniform site can occur in any class or subclass of immunoglobulin by the inser- 
tion of the given short linear sequences. The finding (8) that human antidextran 
of a-(1  --* 6)  specificity may occur in ~/A, 3'M, 3,G2,  and sometimes in ~/G1 
immunoglobulins and may have K- or X-chains  is consistent with but does not 
provide conclusive evidence for this hypothesis, since the human antidextran 
still represents mixtures with heterogeneous sizes of combining sites. More im- 
portant, however, may be the findings of Pincus et al. (14) that rabbit type III 
and type VIII  antibodies to the pneumococcal polysaccharide, which gave a 
straight line of slope not significantly different from 1.0 in a Sips plot for binding 
of  an  octasaccharide  and  could thus be  considered quite homogeneous with 
respect to their antibody-combining sites, showed many light chains and several 
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different antibody molecules could have the same binding affinity and therefore 
probably have  very similar  or  even  identical  combining  sites.  It  would  be 
especially important  to determine whether  such  mixtures  of  antibodies  also 
belonged to different classes  and had  antigenically different light and heavy 
chains. 
Further studies on homogeneous antibodies of a given specificity but of dif- 
ferent classes or subclasses would be predicted to show similar sequences in the 
insertional regions if their sites were identical. Conversely, antibodies of a given 
specificity but showing differences in the degree of cross-reactivity with related 
antigens  would  be  expected  to  show  smaller  differences  in  their  insertion 
regions than would antibodies of totally unrelated specificities. Such data may 
soon become available as  sequences on myeloma proteins with  antibody ac- 
tivity and on homogeneous antibodies are accumulated. 
While  such  findings  would  provide  strong  support  for  the  hypothesis,  it 
should be borne in mind that the contour of an antibody site having a  given 
specificity or binding  affinity for a  given  determinant  could conceivably be 
formed by several kinds of patterns of amino acid sequences. Under such cir- 
cumstances,  antibodies which were homogeneous in binding affinity but were 
mixtures of molecules with different sequences in the hypothesized insertional 
regions would be expected not to give unique sequences in these regions. More- 
over, the possibility exists that binding could be influenced to some extent by 
different residues  adjacent  to a  site but not  in  themselves complementarity 
determining. 
The data on idiotypic specificity of myeloma globulins (68)  and antibodies 
(69-73) are compatible with the insertion model and with the over-all concept 
of antibody structure proposed. Thus idiotypic determinants which are found 
in the variable regions would represent antigenic determinants formed by pat- 
terns of amino acid sequences involving some of the side chains of residues from 
the inserted regions--namely those forming the  exterior portions  of the  site 
but also including some of the residues involved in three-dimensional folding 
and belonging to various subgroups, etc. This could give rise to a large number 
of determinants generally not related to specificity but influenced by or indeed 
partly created by the sequence of site-determining residues. In many instances 
in which immunodominant groups of the idiotypic determinants were from those 
of the inserted regions, one might expect the same idiotypic specificity to be 
manifested in several classes of immunoglobulins; this has been shown to be the 
case for ~M and 3'G antibodies from the same rabbit (71). Thus the findings on 
idiotypic specificity provide further support for the uniqueness and universality 
of the antibody-forming mechanism. 
Several models for insertion of information into DNA have been recognized. 
One of these is the episomal model (74,  75),  and another involves two recom- 
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containing  a  large number of short nucleotide sequences  the incorporation of 
any  one of which  into  the  structural  genes of  the light  and  heavy chains  to 
provide  the  information  for  a  given  antibody  complementarity  provides  a 
tempting mechanism.  Such  incorporation  could be during  embryogenesis, by 
which  each cell receives the proper nucleotide sequences to program its struc- 
tural  genes for  a  given antibody specificity. Alternatively,  if  a  cell  is multi- 
potent, it could have a  number of sequences or the entire episome and the in- 
sertion of the proper sequence could be accomplished in some unknown manner 
after antigenic  stimulation.  While  the  evidence shows  that  one cell  produces 
one kind of antibody at a time, and that myeloma cells produce populations of 
molecules which  bind ligands  in  a  homogeneous manner,  such cells would  al- 
ready be programmed. The  hypothesized  programming could  possibly result 
from  the  cell-cell  interactions  for  which  some  evidence  has  been  advanced. 
Systems  of  this  type  include  transfer  of  information  from  macrophages  to 
lymphoid cells (78)  and two cell interactions such as thymus-bone marrow, etc. 
(16,  p. 431,  79  81).  There is no basis at present for any more than  a  passing 
reference to these as possibilities. 
Placing  the  information  for  site  complementarity  in  an  independent  self- 
duplicating  mechanism  would  provide  the  evolutionary  stability  needed.  It 
would lead to the  universality which  the  antibody-forming system has clearly 
manifested, because the requirements for successful insertion would be relatively 
more stringent so that changes in  the  insertion material would have a  higher 
frequency for completely destroying the capacity to form antibodies and such 
individuals would probably not survive. 
There are difficulties in  applying the episomal model to the  antibody com- 
plementarity problem. The insertion in the antibody case would have to be by 
a  recombination mechanism involving overlapping sequences  on  each side  as 
in the P1 phage transduction,  rather than as in the Campbell model. However, 
the  degree of overlap on  each side of  the postulated  insertions  is very small, 
e.g.,  an invariant Cys at the beginning and invariant Trp 35 and Phe 98 at the 
end.  Moreover episomes have not  been found  to  date  except in  bacteria,  al- 
though several possibly relevant systems in eukaryotes have been noted  (74). 
It is also difficult to see how insertions to produce a given antibody specificity 
could be programmed for both the light and heavy chains since their contribu- 
tions to binding are generally quite different. 
The insertion model does not necessarily distinguish between germ line and 
somatic theories, for generating the diversity necessary to provide a large num- 
ber of sites. Such diversity could be  obtained  by  the  existence  of  a  large dic- 
tionary  of insertions  each  of which  determined  a  given specificity,  e.g.  by a 
germ line theory, or by the recombination of the nucleotides within the insertion 
material of a relatively small number of different sequences to produce a large 
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formation of site-determining sequences which were not exactly the same for a 
given antibody in different species or in different individuals.  Should sequence 
data on homogeneous antibodies  to a  given antigenic determinant formed in 
various species show that the same sequence is complementarity determining, 
the dictionary model would be favored over the recombinational version. Sim- 
ilarly, if homogeneous antibodies to a given determinant in the same individual 
but belonging to the various classes (3'G, 3'M, 3'A) or subclasses (3'GI, 3'G2, etc.) 
of immunoglobulins have  the  same complementarity determining residues,  a 
dictionary model would also be favored. 
The suggestions put forward are admittedly speculative as is the case at the 
moment with  all other hypotheses.  They do however present  the problem of 
the  antibody-combining site  and  of immunoglobulin  structure  in  a  different 
way, but in  a  way which is susceptible  to verification or disproof by further 
data.  Whether  the  model  proposed  ultimately  stands  or  falls,  the  effort  to 
assign  each  amino  acid  residue  in  the  variable region  a  definite  role  by the 
statistical  analysis employed should prove useful. 
SUMMARY 
In  an  attempt to account for antibody specificity and complementarity in 
terms of structure, human ~-, human X-, and mouse K-Bence Jones proteins and 
light chains are considered as a single population and the variable and constant 
regions are compared using the sequence data available. Statistical criteria are 
used in evaluating each position in the sequence as to whether it is essentially 
invariant or group-specific, subgroup-specific, species-specific, etc. 
Examination of the invariant residues of the variable and constant regions 
confirms the  existence  of a  large number  of invariant  glycines,  no invariant 
valine, lysine, and histidine,  and only one invariant leucine and alanine in the 
variable region, as compared with the absence of invariant glycines and pres- 
ence  of three  each  of invariant  alanine,  leucine,  and  valine  and  two each  of 
invariant lysine and histidine in  the  constant region.  The unique  role of gly- 
cine in the variable region is emphasized. Hydrophobicity of the invariant resi- 
dues  of the  two regions is  also  evaluated.  A  parameter termed variability is 
defined  and  plotted  against  the  position for the  107  residues  of  the variable 
region.  Three  stretches  of  unusually  high  variability  are  noted  at  residues 
24-34,  50-56,  and 89-97; variations in length have been found in the first and 
third  of these.  It is hypothesized that positions 24-34  and 89-97  contain  the 
complementarity-determining residues  of  the  light  chain--those  which  make 
contact  with  the  antigenic  determinant.  The  heavy chain  also  has  been  re- 
ported to have a similar region of very high variability which would also par- 
ticipate in forming the antibody-combining site.  It is postulated  that the in- 
formation  for  site  complementarity is  contained  in  some  extrachromosomal 
DNA  such  as an episome and  is incorporated  by insertion  into  the  DNA  of 246  BENCE JONES PROTEINS AND MYELOMA LIGHT CHAINS 
the structural genes for the variable region of short linear sequences of nucleo- 
tides.  The advantages and disadvantages  of this hypothesis are discussed. 
BIBLIOGRAPHY 
1.  Kabat, E. A. 1966. The nature of an antigenic determinant. J. Immunol. 97:1. 
2.  Kabat, E. A. 1968. Structural Concepts in Immunology and Immunochemistry. 
Holt, Rinehart & Winston, Inc., New York. 
3.  Goodman, J. W. 1969. Immunochemical specificity: Recent conceptual advances. 
Immunochemistry. 6:139. 
4.  Cohen, S., and R. R. Porter.  1964. Structure and biological activity of immuno- 
globulins. Advan. Immunol. 4:287. 
5.  Kabat,  E.  A.  1966.  Structure  and  heterogeneity  of  antibodies.  Acta  haematol. 
36:198. 
6.  Cohen, S,, and C. Milstein,  1967. Structure and biological properties of immuno- 
globulins.  Advan. Immunol. 7:1. 
7.  Milstein, C., and J. R. L. Pink. 1970. Structure and evolution of immunoglobulins. 
Prog.  Biophys. Mol. Biol. 21:209. 
8.  Yount, W. J., M. M. Dorner, H. G. Kunkel, and E. A. Kabat.  1968. Studies on 
human antibodies. VI. Selective variations in subgroup composition and genetic 
markers. J. Exp. Med. 19.7:633. 
9.  Dorner, M. M., W. J. Yount, and E. A. Kabat. 1969. Studies on human antibodies. 
VII. Acrylamide gel electrophoresis of purified human antibodies and myeloma 
proteins, their heavy and light chains. J. ImmunoL 109.:273. 
i0.  Fleischman,  J.  B,, D. G. Braun, and R. M.  Krause.  1968. Streptococcal group- 
specific  antibodies:  Occurrence of a  restricted  population following secondary 
immunization. Proc. Nat. Acad. Sci. U. S. A. 60:134. 
11. Braun, D. G., and R. M. Krause. 1968. The individual antigenic specificity of anti- 
bodies to streptococcal carbohydrates. J. Exp. Med. 128:969. 
12.  Eichmann,  K.,  H.  Lackland,  L.  Hood, and  R.  M.  Krause.  1970. Induction of 
rabbit  antibody with molecular uniformity after immunization with group C 
streptococci, f . Exp. Med. 131:207. 
13.  Pappenheimer, A. M., Jr., W. P. Reed, and R. Brown. 1968. Quantitative studies 
of the specificity of anti-pneumococcal polysaccharide antibodies, types III and 
VIII. III. Binding of a labeled oligosaccharide derived from $8 by anti-S8 anti- 
bodies. J. Immunol. 100:1237. 
14.  Pincus, J. H., E. Haber, M. Katz, and A. M. Pappenbeimer, Jr. 1968. Antibodies 
to pneumococcal polysaccharides: Relation between binding and electrophoretlc 
heterogeneity. Science  (Washington) 165:667. 
15.  Brenneman, L., and S. J. Singer.  1968. The generation of antihapten antibodies 
with electrophoretically homogeneous L chains. Proc. Nat, Acad. Sci.  U. S. A. 
60:258. 
16.  Frisch, L., editor.  1967. Antibodies. Cold Spring Harbor Syrup. Quant. Biol. 39.:1- 
603. 
17.  Rossi, G., T. K. Choi, and A. Nisonoff. 1969. Crystals of fragment F~b': Prepara- 
tion  from pepsin  digests  of human IgG myeloma proteins.  Nature  (London) 
9.23:837. TAI TE  WU AND ELVIN A.  KABAT  247 
18.  Killander, J., editor. 1967. Gamma Globulins. Nobel Symp. 3:17~43. 
19.  Beaumont,  J.  L.  1967.  Une  sp6cificit6  commune  aux  a-  et/3-lipoprot6ines  du 
s6rum  r6v616e par  un autoanticorps  de my61ome-L'antigSne Pg.  C.  R.  Acad. 
Sci Ser. D. 264:185. 
20.  Eisen, H. N., E. S.  Simms, and M. Potter.  1968. Mouse myeloma proteins with 
antihapten  antibody  activity.  The  protein  produced  by  plasma  cell  tumor 
MOPC-315. Biochemistry. 7:4196. 
21.  Metzger, H., and M. Potter. 1968. Affinity site labeling of a mouse myeloma pro- 
tein which binds dinitrophenyl ligands. Science (Washington). 162:1398. 
22.  Potter,  M.,  and M. A. Leon.  1968. Three IgA myeloma immunoglobulins from 
BALB/c  mouse:Precipitation  with  pneumococcal  C  polysaccharide.  Science 
(Washington). 162:369. 
23.  Schubert, D., A. Jobe, and M. Cohn. 1968. Mouse myeloma producing precipitat- 
ing  antibody  to  nucleic  acid  bases  and/or  nitrophenyl  derivatives.  Nature 
(London). 220:882. 
24.  Ashman, R. F., and H. Metzger. 1969. A Waldenstr6m macroglobulin which binds 
nitrophenyl ligands. J. Biol. Chem. 244:3405. 
25.  Colin. M., G. Notani, and S. A. Rice. 1969. Characterization of the antibody to the 
C-carbohydrate produced by a transplantable  mouse plasmacytoma. Immuno- 
chemistry. 6:111. 
26.  Capra, J. D., D. Wertheimer, W. J. Yount, and H. G. Kunkel. 1969. Monoclonal 
"yG anti-~? globulins in hypergammaglobulinemic purpura. Clin. Res. 17:351. 
27.  American Association o[ Immunologists Symposium on Experimental Approaches 
to Homogeneous Antibody Populations. 1970. Fed. Proc. 29:55-91. 
28.  Potter, M. 1967. The plasma cell tumors and myeloma proteins of mice. Methods 
Cancer Res. 2:106. 
29.  Edelman, G. M., and J. A. Gally. 1962. The nature of Bence Jones proteins. Chem- 
ical similarities to polypepfide chains of myeloma globulins and normal ~{-globu- 
lins. J. Exp. Med. 116:207. 
30.  Quattrocchi, R., D. Cioli, and C. Baglioni. 1969. A study of immunoglobulin struc- 
ture.  III. An estimate of the variability of human light chains. J. Exp  Med. 
130:401. 
31.  Lennox, E. S., and M. Cohn. 1967. Immunoglobulins. Annu. Rev. Biochem. 36:365. 
32.  Cohn, M.  1968. The molecular biology of expectation.  In Nucleic Acids in Im- 
munology. O. J.  Plescia,  and W. Braun,  editors.  Springer-Verlag, New York. 
671. 
33.  Edelman, G. M., and W. E. Gall.  1969. The antibody problem. Annu.  Rev. Bio- 
chem. 38:415. 
34.  Hood, L., and D. W. Talmage.  1969. On the mechanism of antibody diversity: 
Evidence  for the  germ line basis  of antibody variability.  In  Symposium on 
Developmental  Aspects  o[  Antibody  Formation  and  Structure,  Prague.  In 
press. 
35.  Hood, L., and D. W. Talmage.  1970. Mechanism and antibody diversity: Germ 
line basis for variability. Science (Washington)  168:325. 
36.  Dreyer, W. J., and J. C. Bennett. 1965. The molecular basis of antibody formation: 
A paradox. Proc. Nat. Acad. Sci. U. S. A. 54:864. 
37.  Lederberg, J. 1959. Genes and antibodies. Science  (Washington). 19.9:1649. 248  BENCE  JONES  PROTEINS  AND  MYELOMA  LIGHT  CHAINS 
38.  Burnet, M.  1966. A possible genetic basis for specific pattern in antibody. Nature 
(London).  210:1308. 
39.  Brenner, S., and C. Milstein. 1966. Origin of antibody variation. Nature (London). 
211:242. 
40.  Kabat, E. A. 1967. The paucity of species-specific amino acid residues in the vari- 
able regions of human and mouse Bence Jones proteins and its evolutionary and 
genetic implications. Proc. Nat. Acad. Sci. U. S. A. 57:1345. 
41.  Kabat, E. A. 1967. A comparison of invariant residues in the variable and constant 
regions of human K, human L  and mouse K  Bence Jones proteins. Proc. Nat. 
Acad. Sci.  U. S. A. 58:229. 
42.  Kabat, E. A. 1968. Unique features of the variable regions of Bence Jones proteins 
and their possible relation to antibody complementarity. Proc. Nat. Acad. Sci. 
U. S. A.89:613. 
43.  Kabat, E. A. 1969. Antibody complementarity and light chain structure. In Sym- 
posium  on  the Evolution of Immune  Response.  Oct.  20-22,  1969.  U.S.  Ar- 
gonne National Laboratories, Lemont, Ill. 
44.  Fitch, W. M., and E. Margoliash. 1967. Construction of phylogenetic trees. Sci- 
ence (Washington).  155:279. 
45.  Kabat,  E.  A.  1970. Heterogeneity  and  structure  of  antibody-combining sites. 
Ann. N. Y. Acad.  Sci.  169:43. 
46.  Phillips, D. C. 1967. The hen egg-white lysozyme molecule. Proc. Nat. Acad.  Sci. 
U. S. A. 57:484. 
47.  Milstein, C. 1967. Linked groups of residues in immunoglobulin K  chains. Nature 
(London).  216:330. 
48.  Niall, H., and P. Edman.  1967. Two structurally distinct classes of kappa-chains 
in human immunoglobulins. Nature (London). 216:262. 
49.  Fran~k, F. 1969. The character of variable sequences in immunoglobulins and its 
evolutionary origin.  In  Symposium  on  Developmental Aspects  of  Antibody 
Formation and Structure, Prague. In press. 
50.  Jukes, T. H.  1969. Evolutionary pattern of specificity regions in light chains of 
immunoglobulins. Biochem. Genet. 3:109. 
51.  Welscher, H. D.  1969. Correlations between amino acid sequence and conforma- 
tion  of immunoglobulin light chains.  I. Hydrophobicity and  fraction charge. 
Int. J. Protein Res. 1:235.  II. Sequence comparison and the pattern of nonpolar 
residues. Int. J. Protein Res. 1:267. 
52.  Blake, C. C. F., A. G. Mair, A. C. T. North, D. C. Phillips, and V. R. Sarma. 1967. 
On  the conformation of the hen egg-white lysozyme molecule. Proc.  Roy.  Soc. 
Ser. B. Biol. Sci. 167:365. 
53.  Birktoft, J. J., B. W. Matthews,  and D.  M.  Blow.  1969. Atomic coordinates of 
tosyl-a-chymotrypsin. Biochem. Biophys. Res. Commun. 86:131. 
54.  Edsall, J.  T.,  P.  L.  Flory, J.  C.  Kendrew, A. M.  Liquori,  G. Nfimethy, G. N. 
Ramachandran, and H. A. Scheraga. 1966. A proposal of standard conventions 
and nomenclature for the description of polypeptide con[ormations. Biopolymers 
4:121. 
55.  Ramachandran, G. N., and V. Sasisekharan. 1968. Conformation of polypeptides 
and proteins. Advan. Protein Chem. 23:283. TAI  TE  WU  AND  ELVIN  A.  KABAT  249 
56.  Press, E. M., and N. M. Hogg. 1969. Comparative study of two immunoglobulin 
G Fd-fragments. Nature (London). 223:807. 
57.  Cunningham, B. A., M. N. Pflumm, U. Rutishauser,  and G. M. Edelman.  1969. 
Subgroups of amino acid sequences in the variable regions of immunoglobulin 
heavy chains. Proc. Nat. Acad. Sci. U. S. A. 64:997. 
58.  Tanford, C. 1962. Contribution of hydrophobic interactions to the stability of the 
globular conformation of proteins. J. Amer. Chem. Soc. 84:4240. 
59.  Bigelow,  C. C. 1967. On the average hydrophobicity of proteins and the relation 
between it and protein structure. J. Theor. Biol. 16:187. 
60.  RufSlli,  A., and C. Baglioni. 1967. Subgroups of L  type Bence Jones proteins. J. 
Immunol. 98:874. 
61.  l~uffilli, A. 1968. The antigenic determinants of the variable half of a Bence Jones 
protein of type L. J. Immunol. 100:201. 
62.  Hood, L., H. Lackland, K. Eichmann, J.  Ohms, and R. M.  Krause.  1970.  Amino 
acid  sequences  from  rabbit  antibody  light  chains  and  gene  evolution.  In 
preparation. 
63.  Todd, C. W. 1963. Allotypy in rabbit  19S protein. Biochem. Biophys. Res. Com- 
mun. 11:170. 
64.  Todd, C. W. 1966. Discussion. J. Cell. Physiol. 67(Suppl. 1) :95. 
65.  Koshland, M. E., J. J. Davis, and N. J. Fujita.  1969. Evidence for multiple gene 
control of a single polypeptide chain: The heavy chain of rabbit immunoglobu- 
lin. Proc. Nat. Acad. Sci. U. S. A. 63:1274. 
66.  Smithies,  O.  1963.  Gamma-globulin  variability:  A  genetic  hypothesis.  Nature 
(London). 199:1231. 
67.  Edelman,  G.  M.,  and  J.  A.  Gally.  1967.  Somatic recombination  of duplicated 
genes: An hypothesis on the origin of antibody diversity. Proc. Nat. Acad. Sci. 
U. S. A. 57:353. 
68.  Slater, R. J., S. M. Ward, and H. G. Kunkel.  1955. Immunological relationships 
among the myeloma proteins. J. Exp. Med. 101:85. 
69.  Kunkel, H. G., M. Mannik, and R. C. Williams. 1963. Individual antigenic specific- 
ities of isolated antibodies. Science (Washington) 140:1218. 
70.  Oudin, J., and M. Michel.  1963. Une nouvelle forme d'allotypie des globulines 
de s~rum  de lapin apparemment li~6 h la jonction et ~ la specificit~  anticorps. 
C. R. Acad. Sci. 257:805. 
71.  Oudin, J., and M. Michel.  1969. Idiotypy of rabbit antibodies. I. Comparison of 
idiotype of antibodies against Salmonella typhi with that of antibodies against 
other bacteria in the same rabbit,  or of antibodies against Salmonella typhi in 
various rabbits.  J. Exp.  Med.  130:595.  II. Comparison of idiotypy of various 
kinds of antibodies formed in the same rabbit against Salmonella typhi. J. Exp. 
Med. 130:619. 
72.  Daugharty, H., ~1. E. Hooper, A. B. MacDonald, and A. Nisonoff. 1969. Quantita- 
tive investigations of idiotypic antibodies. I. Analysis of precipitating antibody 
populations. J. Exp. Med. 130:1047. 
73.  Hurez, D., G. Meshaka, C. Mihaesco, and M. Seligmann. 1968. The inhibition by 
normal ")'G-globulins of antibodies specific for individual 5'G myeloma proteins. 
J. Immunol. 100:69. 250  BENCE  JONES  PROTEINS  AND  MYELOMA  LIGHT  CHAINS 
74.  Campbell, A. M. 1962. Episomes. Advan. Genes. 11:101. 
75.  Campbell, A. M. 1969. Episomes. Harper & Row, Publishers, New York. 
76.  Lennox, E. S  1955. Transduction of linked genetic characters of the ho~t by bac- 
teriophage P 1. Virology.  1:190. 
77.  Ozeki, H., and H. Ikeda. 1968. Transduction mechanisms. Annu. Rev. Genet. $:245. 
78.  Adler, F. L.,  M.  Fishman, and S. Dray.  1966.  Antibody formation initiated in 
vitro.  III. Antibody formation and allotypic specificity directed by ribonucleic 
acid from peritoneal exudate cells. ]. Immunol. 97:554. 
79.  Miller, J. F. A. P., and G. F. Mitchell. 1968. Cell to celt interaction in the immune 
response.  I.  Hemolysin-formlng cells  in  neonatally  thymectomized  mice  re- 
constructed with thymus or thoracic duct lymphocytes. J. Exp. Med. 128:801. 
80.  Mitchell, G. F., and J. F. A. P. Miller. 1968. Cell to cell interaction in the immune 
response. II. The  source of hemolysin-forming cells in irradiated mice given 
bone marrow and thymus or thoracic duct lymphocytes. J. Exp. Med. 158:821. 
81.  Clam.an, H. N., E. A. Chaperon, and R. F. Triplett. 1966. Immunocompetence of 
transferred tl~ymus-marrow cell combinations. J. Immunol. 97:828. 